Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Gallagher, Emily J ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; CYCLOOXYGENASE 2; CYTOKINE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TAMOXIFEN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; ESTROGEN ACTIVITY; ETHNIC DIFFERENCE; FAMILY HISTORY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIFESTYLE; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; RISK FACTOR; SMOKING; TUMOR GROWTH; WAIST CIRCUMFERENCE;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; METABOLIC SYNDROME X; NEOPLASMS; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84891763374     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2001     Document Type: Article

References (85)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638
2. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Bio-chem 2008;114:71-83
3. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-565
4. Yang Y, Dong J, Sun K, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer 2013;132:1162-1169
5. Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. Int J Epidemiol 2011; 40:174-182
6. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-1244
7. Cao Y, DePinho RA, Ernst M, Vousden K. Cancer research: past, present and future. Nat Rev Cancer 2011;11:749-754
8. Mente A, Razak F, Blankenberg S, et al.; Study of the Health Assessment And Risk Evaluation; Study of the Health Assessment And Risk Evaluation in Aboriginal Peoples Investigators. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care 2010;33:1629-1634
9. Anand SS, Yusuf S, Jacobs R, et al. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet 2001;358:1147-1153
10. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
11. Parr CL, Batty GD, Lam TH, et al.; Asia-Pacific Cohort Studies Collaboration. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424, 519 participants. Lancet Oncol 2010;11:741-752
12. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review. Obes Rev 2012;13:985-1000
13. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012;55:1607-1618
14. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167
15. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012;35:1835-1844
16. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of death in men with prevalent diabetes and newly diagnosed high-versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;77: 1329-1337
17. Schrauder MG, Fasching PA, Häberle L, et al. Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol 2011;137:975-983
18. Varlotto J, Medford-Davis LN, Recht A, et al. Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer 2012;75:381-390
19. Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci 2010;55:1839-1851
20. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685
21. Gordon-Dseagu VL, Shelton N, Mindell JS. Epidemiological evidence of a relationship between type-1 diabetes melli-tus and cancer: a review of the existing literature. Int J Cancer 2013;132:501-508
22. Stocks T, Borena W, Strohmaier S, et al. Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol 2010;39:660-667
23. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009;6: e1000201
24. Häggström C, Stocks T, Rapp K, et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 2011;128:1890-1898
25. Bjørge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Bio-markers Prev 2010;19:1737-1745
26. Borena W, Stocks T, Jonsson H, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011;22:291-299
27. Stocks T, Van Hemelrijck M, Manjer J, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012;59:802-810
28. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51
29. Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 2011;29:47-53
30. Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121:368-376
31. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149:461-471
32. Morris JK, George LM, Wu T, Wald NJ. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 2006;95:112-117
33. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulinlike growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-1353
34. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide levels and risk of breast cancer among predominately pre-menopausal women. Cancer Epidemiol Biomarkers Prev 2007;16:161-164
35. Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70:741-751
36. Ferguson RD, Novosyadlyy R, Fierz Y, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 2012;14:R8
37. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030-1035
38. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tu-morgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2011; 17:2314-2327
39. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010;107:10791-10798
40. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997;109:565-571
41. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 2012;22:108-115
42. Huang J, Morehouse C, Streicher K, et al. Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 2011;6:e26177
43. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270
44. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134:703-707
45. Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011;13:310-316
46. Nunez NP, Oh WJ, Rozenberg J, et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 2006;66:5469-5476
47. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7, 12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972;32:226-232
48. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-567
49. Johnson JA, Bowker SL. Intensive gly-caemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31
50. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011;54:1608-1614
51. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-197
52. Le TN, Nestler JE, Strauss JF 3rd, Wickham EP 3rd. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012;23:32-40
53. Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res 2010;70:4-7
54. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011;4:1021-1029
55. Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal 2012;24: 1515-1521
56. Periyasamy-Thandavan S, Takhar S, Singer A, et al. Insulin-like growth factor 1 attenuates antiestrogen-and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res 2012;14:R52
57. Pritchard KI, Shepherd LE, Chapman JA, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 2011;29:3869-3876
58. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulinlike growth factor receptor: implications for breast cancer treatment. Cancer Res 2012;72:3372-3380
59. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011;22:1545-1552
60. Furberg AS, Jasienska G, Bjurstam N, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005;14:33-40
61. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011;71: 1763-1771
62. Simons K, Ikonen E. How cells handle cholesterol. Science 2000;290:1721-1726
63. Rysman E, Brusselmans K, Scheys K, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010;70:8117-8126
64. Sikkeland J, Lindstad T, Saatcioglu F. Analysis of androgen-induced increase in lipid accumulation in prostate cancer cells. Methods Mol Biol 2011;776:371-382
65. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 2012;7: e30062
66. Alikhani N, Ferguson RD, Novosyadlyy R, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hy-perlipidemic mouse model. Oncogene. 2 April 2012 [Epub ahead of print]
67. Llaverias G, Danilo C, Mercier I, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011;178:402-412
68. Lappano R, Recchia AG, De Francesco EM, et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor a-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 2011;6:e16631
69. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. In-terleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904-910
70. Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011;2: 384-396
71. Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial-mes-enchymal transition phenotype in human breast cancer cells. Oncogene 2009;28: 2940-2947
72. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R, Cheng PW. TNFa enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl-and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Commun 2011;409:436-441
73. Flores MB, Rocha GZ, Damas-Souza DM, et al. Obesity-induced increase in tumor necrosis factor-alpha leads to development of colon cancer in mice. Gastroenterology 2012;143:741-753
74. Subbaramaiah K, Howe LR, Bhardwaj P, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011;4:329-346
75. Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumori-genesis. Mol Cell 2012;45:777-789
76. D'Anello L, Sansone P, Storci G, et al. Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer 2010;9: 300
77. Kim SW, Kim JS, Papadopoulos J, et al. Consistent interactions between tumor cell IL-6 and macrophage TNF-a enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Im-munopharmacol 2011;11:862-872
78. Ho GY, Wang T, Gunter MJ, et al. Adi-pokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012;72:3029-3037
79. Macciò A, Madeddu C, Gramignano G, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl) 2010;88:677-686
80. Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in pre-menopausal women. Cancer Prev Res (Phila) 2011;4:1449-1456
81. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adipo-nectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56:34-43
82. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009;20:193-201
83. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:s858-s866
84. Bråkenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antiangio-genesis and antitumor activity involve caspase-mediated endothelial cell apo-ptosis. Proc Natl Acad Sci USA 2004;101: 2476-2481
85. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007; 98:1120-1127